Ardent Health Partners, Inc. (ARDT) closed the last trading session at $14.83, gaining 19.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $20.25 indicates a 36.6% upside potential.The average comprises 10 short-term price targets ranging from a low of $15.50 to a high of $24, with a standard deviation of $2.80. While the lowest estimate indicates an increase of 4.5% from the cur ...

Tectonic Therapeutic, Inc. (TECX) closed the last trading session at $20.71, gaining 15.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $74.25 indicates a 258.5% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $20.71. While the lowest estimate of $51 indicates a 146.3% increase from the current price level, the most optimis ...

Treace Medical Concepts (TMCI) closed the last trading session at $7.20, gaining 6.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10.16 indicates a 41.1% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $2.16. While the lowest estimate of $8 indicates an 11.1% increase from the current price level, the most optimistic ana ...

NewAmsterdam Pharma Company N.V. (NAMS) closed the last trading session at $18.37, gaining 21.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $42.71 indicates a 132.5% upside potential.The average comprises seven short-term price targets ranging from a low of $37 to a high of $52, with a standard deviation of $5.28. While the lowest estimate indicates an increase of 101.4% from ...

Nuvectis Pharma, Inc. (NVCT) closed the last trading session at $9.22, gaining 8.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19.25 indicates a 108.8% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $4.35. While the lowest estimate of $15 indicates a 62.7% increase from the current price level, the most optimistic analy ...

Tarsus Pharmaceuticals, Inc. (TARS) closed the last trading session at $50.90, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $67.13 indicates a 31.9% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $13.74. While the lowest estimate of $41 indicates a 19.5% decline from the current price level, the most optimist ...

Group 1 - Corbus Pharmaceuticals (CRBP) closed at $6.03, with a 0.5% gain over the past four weeks, and has a mean price target of $52.11, indicating a potential upside of 764.2% [1] - The mean estimate consists of nine short-term price targets with a standard deviation of $12.31, where the lowest estimate is $35 (480.4% increase) and the highest is $73 (1110.6% increase) [2] - Analysts show strong agreement on CRBP's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for CRBP's current year earnings has increased by 0.1% over the last 30 days, with one estimate moving higher and no negative revisions [12] - CRBP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [10][13]